Our expansive research facilities, state-of-the-art technologies and unique location within The Royal Children’s Hospital, are some of the reasons we’re home to over 1,800 leading researchers and scientists.
Stay informed with the latest research insights, technological advancements and innovations in child health from our research and scientific community.
Discover how you can support us and our partners to help our researchers make life-changing breakthroughs for children.
Search throughout the entire MCRI website to find exactly what you are looking for.
Family Foundations is a family-based intervention that focuses on the critical early years of children’s lives and engages all parents/caregivers in the family. The study focuses on strengthening the skills needed to navigate stressful life circumstances and minimise the impact they can have on
Increasing vaccine research capability for immunisation policy decision-making. Immunisation is one of the most powerful health investment tools we have to keep people healthy, prevent disability and save lives. Vaccination plays a key role in promoting improving health equity and addressing
The Vaccine Immunology group conducts research to better understand the human immune response to childhood vaccines and infections. Our focus is aimed at using immunology to identify optimal vaccination strategies in high-risk settings and ultimately to improve child health through improved access
VIRGo conducted vaccine and immunisation research with clinical trials of new vaccines, and epidemiologic studies of vaccine-preventable disease. Our findings enable us to advise policymakers on the optimal use of vaccines in national immunisation schedules, in pandemic influenza preparedness and
Developing and testing better ways to get life-saving oxygen to patients when they need it.
A randomised clinical trial evaluating the efficacy and safety of PVX108, a new immunotherapy designed to precisely retrain the immune system to tolerate peanut allergens and reduce the risk of severe allergic reactions. This a sponsored clinical trial funded by Aravax.
This study is complete. A study of 9,790 participants that aimed to determine the prevalence of true food allergy in early adolescence, understand risk factors for recurrent or severe accidental ingestion reactions among food allergic children, and determine clinical predictors of food challenge
ADAPT is an oral immunotherapy program offered at participating hospitals to eligible babies with peanut allergy. Peanut is the most common cause of childhood food allergy, affecting 3.1 per cent of one-year-olds in Australia. Oral immunotherapy (OIT) is an emerging treatment option that aims to
Researchers have warned that children and adolescents must not be left behind in Australia's COVID-19 recovery plans given the negative indirect impacts of the pandemic on this age group detailed in a new brief and research review by the Murdoch Children's Research Institute. The COVID-19 research
We seek to understand the roles of the many different cell types that make up the immune system, with a focus on unconventional and innate-like T cells.
Page 33 of 188
